ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Q2 revenue ₹1,560 Cr (+20% YoY) and PAT ₹182 Cr (+39%), but EBITDA margin fell 131bps QoQ on West Asia costs. Gagilapur FDA observations leave the warning letter unresolved.
Granules India submitted its monitoring agency report on preferential issue proceeds for quarter ended September 2026. It reports no deviation from stated objects.
Q2 FY27 revenue ₹15,600 Mn (+20% YoY), EBITDA ₹3,376 Mn (21.6% margin), PAT ₹1,818 Mn (+39%). Net cash ₹8,280 Mn after warrant proceeds.
Granules India reported Q2FY27 revenue of INR 15,600 Mn, up 20% YoY, and PAT of INR 1,818 Mn, up 39%. The company also cited a net cash position and a US FDA audit at its Gagillapur site.
Granules India Ltd reported revenue from operations of ₹1,560 Cr (+20.3% YoY) and net profit of ₹181.8 Cr (+39.2% YoY) for Q2 FY27.
Granules' Gagillapur facility received eleven USFDA observations with no impact on product supply. The inspection was the first since a February 2025 Warning Letter.
Chigurupati family promoters disclosed acquiring 2,49,82,906 warrants via preferential allotment on 23 February 2026. Warrants priced at ₹585 each lift diluted promoter-group holding to 43.69%.
Promoter group members Uma Devi, Priyanka, Pragnya and Harsha were allotted 2,49,82,906 Granules India shares on warrant conversion. The balance payment totals about ₹1,096.13 crore.
Promoter Dr Krishna Prasad Chigurupati filed a revised disclosure of selling 1,72,00,000 Granules India shares on 11 September 2026. Promoter group voting stake falls from 38.02% to 31.08%.
Granules India promoter group members acquired warrants and shares in a preferential allotment. Reported consideration totals about Rs.1,461.5 Crore.
Granules India's Board is scheduled for 02 Nov 2026 to consider unaudited Q2/H1 results. No decision has been taken yet; this is a prior intimation only.
Granules India incorporated a wholly owned Mexican subsidiary, Triton Farmaceutica S.A. de C.V., to manufacture and distribute pharmaceuticals in Mexico. Operations have yet to commence.
Granules India Ltd filed its shareholding pattern for the quarter ended September 30, 2026.
Granules India filed a Paragraph IV ANDA certification for Ruxolitinib ER Tablets, claiming potential 180-day U.S. generic exclusivity, subject to FDA review and confirmation.
Granules India Limited incorporated a wholly owned subsidiary, Triton Farmaceutica Do Brasil Ltda, in Brazil to expand its pharmaceutical manufacturing and distribution operations in the region.
Promoter Uma Devi Chigurupati acquired 2.48 crore shares of Granules India Ltd via the open market. This transaction increases the promoter stake by 8.70%.
The company submitted its quarterly shareholding pattern disclosure as required by SEBI regulations for the period ended September 16, 2026.
Granules India allotted 2.49 crore equity shares to its promoter group upon warrant conversion, raising Rs. 1,461.50 Crore. This increases the company's total paid-up equity capital.
Granules India received Rs. 1,093 crore from the Promoter group, representing the balance 75% subscription for the conversion of 2.49 crore warrants into equity shares.
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares of Granules India Ltd via block deal and open market, reducing aggregate promoter stake.
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India Limited announced the internal transfer of Mr. Sanjay Kumar, Chief Strategy Officer, to its subsidiary Ascelis Peptides Private Limited as CEO.